New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
11:20 EDTRMTI, RMTI, AFFY, AFFY, KERX, KERX, AMAG, AMAGSummer Street's biotech research team holds analyst/industry conference call
Biotech Analyst Research Team, along with an MCRI consultant, discuss dialysis and iron products for end-state renal disorders on an Analyst/Industry conference call to be held on January 31 at 11:30 am.
News For RMTI;AFFY;KERX;AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 10, 2014
11:11 EDTKERXKeryx management to meet with Maxim
Subscribe for More Information
December 5, 2014
10:44 EDTRMTIOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTKERXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acorda Therapeutics (ACOR) initiated with a Neutral at Goldman... Builders FirstSource (BLDR) initiated with a Neutral at Sterne Agee... CSI Compressco (CCLP) initiated with a Buy at Stifel... California Resources Corp. (CRC) initiated with a Market Perform at Raymond James... Castlight Health (CSLT) initiated with an Equal Weight at First Analysis... DCP Midstream (DPM) initiated with a Buy at MLV & Co.... DSP Group (DSPG) initiated with an Outperform at Imperial Capital... Edwards Lifesciences (EW) initiated with an Outperform at Bernstein... EnLink Midstream (ENLK) initiated with a Buy at MLV & Co.... Facebook (FB) initiated with a Buy at MKM Partners... FireEye (FEYE) initiated with a Market Perform at JMP Securities... FleetCor (FLT) initiated with a Buy at Deutsche Bank... Imperva (IMPV) initiated with a Buy at Nomura... Keryx (KERX) initiated with an Outperform at Cowen... Knowles (KN) initiated with a Market Perform at FBR Capital... Marlin Midstream (FISH) initiated with a Buy at MLV & Co.... Paragon Offshore (PGN) initiated with a Sector Perform at Iberia... PepsiCo (PEP) initiated with a Buy at Evercore ISI... Proofpoint (PFPT) initiated with a Buy at Nomura... Relypsa (RLYP) initiated with an Outperform at Oppenheimer... Rocket Fuel (FUEL) initiated with a Sell at Maxim... Sprouts Farmers Markets (SFM) initiated with an Underperform at Longbow... Summit Midstream (SMLP) initiated with a Buy at MLV & Co.... TubeMogul (TUBE) initiated with a Buy at Maxim... Western Gas Partners (WES) initiated with a Buy at MLV & Co.
09:19 EDTKERXKeryx initiated with an Outperform at Cowen
Subscribe for More Information
December 4, 2014
10:36 EDTRMTIOptions with increasing implied volatility
Subscribe for More Information
07:41 EDTKERXKeryx issued new U.S. patent for Auryxia
Keryx Biopharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate having a BET active surface area greater than about 16 sq. m/g. The patent also claims a broad category of orally administrable forms covering Auryxia, as well as other oral formulations that could be developed in the future. On September 5, Auryxia was approved by the FDA for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. This newly issued patent further enhances the company's key patent family, which includes U.S. Patent Nos. 7,767,851, 8,299,298, 8,338,642, 8,609,896, 8,754,257, 8,754,258, and 8,846,976 which expire in 2024, and U.S. Patent No. 8,093,423, which expires in 2026, before patent term extension. Each of these patents contains composition and method of use claims covering Auryxia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use